Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L32 pseudogene 35 (RPL32P35) is a processed pseudogene in the human genome, derived from the parental ribosomal protein L32 (RPL32) gene[1][2][5][8]. It does not encode a protein and has no established biological function, disease association, or therapeutic role. Pseudogenes like RPL32P35 are the result of duplication or retrotransposition events and are typically non-functional[1][8]. Unlike its parental gene RPL32, which encodes a component of the 60S subunit of the ribosome essential for protein synthesis, RPL32P35 is transcriptionally inactive and not subject to conventional therapeutic targeting[1][2][10]. If you are seeking information on a druggable ribosomal protein L32 itself, refer to the parental gene RPL32, not this pseudogene[10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L32 pseudogene 35 (RPL32P35).